<DOC>
	<DOCNO>NCT01520441</DOCNO>
	<brief_summary>This pilot study examine biological endpoint men localize prostate cancer schedule radical prostatectomy men Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms ( BPH/LUTS ) follow botulinum toxin type A ( BoNT-A ) injection . Patients serve control receive BoNT-A injection right peripheral transition zone sham saline injection leave peripheral transition zone .</brief_summary>
	<brief_title>BOTOX Men With Prostate Cancer With Lower Urinary Tract Symptoms ( LUTS ) /Benign Prostatic Hyperplasia ( BPH )</brief_title>
	<detailed_description>For purpose study , patient treat presentation botulinum toxin type A market U.S. BOTOX® Allergan . BOTOX® purify neurotoxin complex supply sterile , vacuum dry purified botulinum toxin type A , produce fermentation Clostridium botulinum type A . A primary aim study determine molecular effect BoNT-A injection human BPH tissue . While majority BoNT-A injection human target BPH transition zone , innervation abundant peripheral zone prostate majority prostate cancer develop . In fact , recent study demonstrate importance neurogenesis axogenesis spread human prostate cancer . In addition , vitro study show BoNT-A antiproliferative effect human prostate cancer cell line . Thus , second aim proposal determine profile change high-grade prostatic intraepithelial neoplasia ( HGPIN ) prostate cancer follow BoNT-A injection peripheral zone . The investigator also determine effect BoNT-A genetic profile normal tissue . The investigator study population men clinically localize prostate cancer . Men inject one side transition peripheral zone 100U BoNT-A ( i.e . Botox® , Allergan , Inc. ) , respectively , one month prior schedule radical prostatectomy . Sham saline injection side prostate ( transition peripheral zone ) use internal control . The investigator inject lobe prostate saline account denervating effect `` wet needling . '' Patients undergo radical prostatectomy without change standard care . The strategy use investigator Institution previously determine efficacy gene therapy 22 target drug . However , unlike investigator previous neoadjuvant trial , investigator power study look effect Botox biochemical recurrence free survival . This study biologic endpoint survival endpoint . '' A third aim study examine change vas deferens function follow prostate treatment BoNT-A . The investigator plan harvest 2.5 cm segment distal va deferens either side ( i.e . Saline treat BoNT-A treat ) entry prostate isolate place oxygenated krebs solution transport research laboratory . Patients 3 visit clinic two telephone call participation study . The last visit 4 week injection .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Biopsy proven , clinically localized prostate cancer Low risk recurrence define Kattan nomogram score less 115 , serum PSA &lt; 10ng/ml , individual Gleason grade 3 low , clinical stage T2b . Candidates diagnose localized prostate cancer must agree radical prostatectomy . Voided volume great equal 125 ml . Maximum urinary flow less 15 ml/sec . American Urological Association ( AUA ) symptom severity score great equal 8 . Patient sign informed consent prior performance study procedure . Patient able complete study protocol opinion investigator . Any prior surgical intervention BPH . Current diagnosis acute chronic prostatitis ( may cause LUTS mimic BPH ) . History bladder stone . Overactive bladder without bladder outlet obstruction . Enrolled another treatment trial disease within past 30 day . Previous exposure botulinum toxin . Post void residual great 350 ml . Clinically significant renal hepatic impairment determine abnormal creatinine AST level ( base local institutional value ) . Daily use pad device incontinence require . Episode unstable angina pectoris , myocardial infarction , transient ischemic attack , cerebrovascular accident ( stroke ) within past 6 month . On aminoglycosides drug interfere neuromuscular transmission . EatonLambert syndrome , hemophilia , hereditary clotting factor deficiency , bleed diathesis . Penile prosthesis artificial urinary sphincter . History current evidence carcinoma bladder ; pelvic radiation , hormonal treatment surgery ; urethral stricture ; bladder neck obstruction . Known primary neurologic condition multiple sclerosis , myasthenia gravis Parkinson 's disease , neurological disease know affect bladder function . Two document urinary tract infection type past year ( UTI define great 100,000 colony per ml urine midstream clean catch catheterize specimen ) . Patients must aspirin , nonsteroidal antiinflammatory drug ( NSAIDS ) , Coumadin 7 day prior botulinum toxin injection . Any serious medical condition likely impede successful completion study , certain mental disorder , hypersensitivity botulinum toxin anesthetic use study , syncope , uncontrolled diabetes . Patients exclude depressed hematopoietic function ( platelet count &lt; 100,000/cm3 , hemoglobin &lt; 8,5 mg/dl ; absolute neutrophil count &lt; 1000/cm3 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Botulinum Toxin</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>BPH</keyword>
	<keyword>LUTS</keyword>
</DOC>